Advances in T-cell therapy for ALL

Por Grupp, Stephan A.
Publicado no Best Pract Res Clin Haematol (2014)

mTOR Inhibitors and Their Potential Role in Therapy in Leukemia and Other Haematologic Malignancies

Por Teachey, David T., Grupp, Stephan A., Brown, Valerie I.
Publicado em 2009

Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS)

Por Teachey, David T., Seif, Alix E., Grupp, Stephan A.
Publicado em 2009

Autologous and Allogeneic Cellular Therapies for High-Risk Pediatric Solid Tumors

Por Barrett, David, Fish, Jonathan D., Grupp, Stephan A.
Publicado em 2010

Toxicity management for patients receiving novel T-cell engaging therapies

Por Barrett, David M., Teachey, David T., Grupp, Stephan A.
Publicado em 2014

Roadblocks to success for RNA CARs in solid tumors

Por Singh, Nathan, Barrett, David M, Grupp, Stephan A
Publicado no Oncoimmunology (2015)

Chimeric antigen receptor (CAR) and T cell receptor (TCR) Modified T cells Enter Main Street and Wall Street

Por Barrett, David M, Grupp, Stephan A, June, Carl H
Publicado no J Immunol (2015)

Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies

Por Maude, Shannon L., Barrett, David, Teachey, David T., Grupp, Stephan A.
Publicado em 2014

Targeting the PI3K/AKT/mTOR Signaling Axis in Children with Hematologic Malignancies

Por Barrett, David, Brown, Valerie I., Grupp, Stephan A., Teachey, David T.
Publicado em 2012

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

Por Maude, Shannon L., Teachey, David T., Porter, David L., Grupp, Stephan A.
Publicado no Blood (2015)

Immunotherapy for Pediatric Cancer

Por Grupp, Stephan A., Verneris, Michael, Sondel, Paul M., Cooper, Laurence J. N.
Publicado em 2008

Antibody-modified T cells: CARs take the front seat for hematologic malignancies

Por Maus, Marcela V., Grupp, Stephan A., Porter, David L., June, Carl H.
Publicado em 2014

The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer

Por Lee, Daniel W., Barrett, David M., Mackall, Crystal, Orentas, Rimas, Grupp, Stephan A.
Publicado em 2012

Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease

Por Brown, Valerie I., Seif, Alix E., Reid, Gregor S. D., Teachey, David T., Grupp, Stephan A.
Publicado em 2008

Chimeric Antigen Receptor Therapy for Cancer

Por Barrett, David M., Singh, Nathan, Porter, David L., Grupp, Stephan A., June, Carl H.
Publicado em 2013

Regimen-Specific Effects of RNA-Modified Chimeric Antigen Receptor T Cells in Mice with Advanced Leukemia

Por Barrett, David M., Liu, Xiaojun, Jiang, Shuguang, June, Carl H., Grupp, Stephan A., Zhao, Yangbing
Publicado em 2013

Feasibility of a Tandem Autologous Peripheral Blood Stem Cell Transplant Regimen for High Risk Neuroblastoma in a Cooperative Group Setting: a Pediatric Oncology Group Study

Por Granger, Meaghan, Grupp, Stephan A., Kletzel, Morris, Kretschmar, Cynthia, Naranjo, Arlene, London, Wendy B., Diller, Lisa
Publicado no Pediatr Blood Cancer (2012)

Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling

Por Brown, Valerie I., Fang, Junjie, Alcorn, Keith, Barr, Rosalind, Kim, Jenny M., Wasserman, Robert, Grupp, Stephan A.
Publicado em 2003

Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses

Por Seif, Alix E., Barrett, David M., Milone, Michael, Brown, Valerie I., Grupp, Stephan A., Reid, Gregor S. D.
Publicado em 2009

Relation of clinical culture method to T cell memory status and efficacy in xenograft models of adoptive immunotherapy

Por Barrett, David M., Singh, Nathan, Liu, Xiaojun, Jiang, Shuguang, June, Carl H., Grupp, Stephan A., Zhao, Yangbing
Publicado em 2014